The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Inflammation-Immunology
Inflammation-related diseases are a class of diseases caused by chronic or excessive inflammation, including rheumatoid arthritis, inflammatory bowel disease, autoimmune diseases, etc. The occurrence of these diseases is often associated with abnormal responses of the immune system, leading to chronic inflammation and damage of tissues and organs. Symptoms of inflammation-related diseases include joint pain, intestinal problems, skin lesions, and more. Treatment strategies include anti-inflammatory drugs, immunosuppressants, biologics, etc., aimed at controlling inflammation, relieving symptoms, and maintaining patients' quality of life.
Related Experimental Schemes
